From the Leader's Desk 

I am delighted to share that Syngene sustained positive performance in the fourth quarter of the prior fiscal year, delivering strong full-year results. Our full-year revenue from operations was up 23%, exceeding the upgraded guidance provided earlier in the year (read press release).

We look forward to continued growth in the coming year across our business divisions of Discovery, Development, and Manufacturing.

In other news, as part of our reach out to the scientific community, we recently conducted a scientific symposium at MassBio, Cambridge, titled "Proximity Matters" on targeted protein degradation and stabilization. The symposium received an overwhelming favorable response.

As before, this newsletter edition has an interesting line-up of articles for you.

Happy reading!

In the Spotlight

Safety Assessment: Assessing the safety profile of new drugs through IND-enabling toxicity studies

Syngene offers a full range of IND-enabling exploratory studies, Good Laboratory Practices (GLP) standard tox studies, and specialty studies, as a one-stop safety assessment solution for clients. This includes in vivo and in vitro toxicology services (rodents and non-rodents) for the comprehensive, non-clinical development of pharmaceuticals, agrochemicals, cosmetics, and food ingredients. With an AAALAC-accredited, GLP-certified vivarium and state-of-the-art laboratory, we have completed 500 in vivo and over 750 in vitro Tox studies in the last 5 years.

Viewpoint

Transforming toxicity testing: Embracing a Computational & Data Sciences approach

Although animal experiments have been the traditional gold standard for toxicity testing, there are shortcomings in their correlation with adverse human outcomes. Added to this are the ethical, commercial, and legislative considerations which call for a paradigm shift. In this viewpoint, we discuss how Syngene's Computational & Data Sciences unit offers in silico toxicity assessment across various levels of complexity to enable holistic, mechanism-driven toxicity assessment. various levels of complexity to enable holistic, mechanism-driven toxicity assessment.

New at Syngene

Oligonucleotide services: Syngene adds discovery-scale synthesis

We recently added a discovery-scale oligonucleotide synthesis capability ranging from 50 nmol up to 200 μmol. The facility is equipped with a K&A synthesizer with 16-channel throughput. With this addition, Syngene now offers end-to-end oligonucleotide services ranging from Discovery to cGMP manufacturing (4 mmol to 45 mmol), enabling faster development at lower costs.

Customer Recognition

Syngene scientists recognized for their contribution to leukaemia research

Syndax Pharmaceuticals recently recognized two Syngene scientists for their contribution to Leukaemia research at the American Association of Cancer Research (AACR) conference in Orlando, Florida. Our scientists have been named co-authors in a paper titled 'Characterization of acquired resistance mutations to menin inhibitors' published in the AACR journal.

© 2023, Syngene International Ltd. Syngene International Ltd.

Biocon Park, SEZ, Bommasandra Industrial Area - Phase-IV Bangalore 560099 India